Operation Trailblazer and the clinical trial access gap

On June 23, 2026, the US Department of Health and Human Services launched Operation Trailblazer, a cross-agency initiative coordinated across the FDA, NCI, NCATS, NIH, ARPA-H, and ONC to accelerate and modernize the US clinical trial system. The program responds to a competitive shift that is no longer theoretical. China surpassed the US in total registered clinical trials, accounting for 39% of global trial registrations with more than 7,100 trials, underscoring how quickly the competitive center of gravity is shifting. China had already overtaken the US in Phase 1 trial share for the first time in 2021, and by 2025, global companies had spent more than $137 billion licensing China-based assets.

The initiative is significant, and long overdue. But a closer look at the program's design reveals a structural gap that will determine whether faster approvals translate into faster access for patients. Operation Trailblazer addresses the regulatory and timeline side of the equation. What it largely leaves unaddressed is the patient-finding infrastructure that determines whether approved therapies actually reach the people who need them.

What Operation Trailblazer gets right

The scope of Operation Trailblazer is ambitious. Its sub-initiatives target several of the clearest bottlenecks in US trial infrastructure, from regulatory complexity to interoperability gaps between trial systems.

One sub-initiative in particular stands out: THRIVE (Treating Hereditary Rare Diseases with In Vivo Precision Genetic Medicines), which focuses on accelerating development pathways for in vivo precision genetic medicines targeting hereditary rare diseases. Given that only 5% of rare diseases currently have FDA-approved treatments, any initiative that reduces regulatory barriers for this category of therapy has immediate relevance.

The program also recognizes something important: the US trial system is losing ground not because the science is inferior, but because the operational and regulatory environment has made it harder, slower, and more expensive to run trials domestically. Streamlining regulatory pathways, improving data interoperability, and creating clearer development tracks for emerging modalities are all necessary interventions.

Where the gap becomes visible

The challenge is that regulatory acceleration solves only part of the problem. Even when a therapy moves faster through development, it still needs patients.

This is where the current system consistently breaks down. 80% of clinical trials fail to meet their enrollment deadlines. Recruitment delays account for a disproportionate share of overall trial cost and duration, particularly in precision medicine and rare disease programs where eligible patient populations are small, geographically dispersed, and often undiagnosed.

For genetically stratified therapies, the enrollment challenge is even more acute. Patients must be identified, screened, genetically tested, and qualified through a process that typically involves multiple disconnected vendors, siloed data, and manual coordination. Each handoff introduces delay, drop-off risk, and data loss. The result is that sponsors often know a therapy works long before they can find enough patients to prove it at scale.

Operation Trailblazer addresses major federal and operational bottlenecks in trial modernization. What remains less developed is the infrastructure between patient identification and enrollment.

Gene therapies highlight the delivery gap

The THRIVE sub-initiative brings this tension into sharp focus. Gene therapies and precision genetic medicines represent some of the most promising developments in rare disease treatment. They are also among the hardest to deliver to patients in practice.

Consider Casgevy, the first CRISPR-based gene therapy approved by the FDA. As of June 2025, only 29 patients globally had received treatment, despite the therapy being approved about 18 months earlier. The bottleneck was the operational infrastructure required to find eligible patients, connect them with qualified treatment centers, and coordinate the complex logistics of gene therapy delivery.

This pattern is common across the rare disease landscape. Regulatory approval creates the legal pathway. But reaching patients requires a different kind of infrastructure: one that connects diagnosis, screening, genetic testing, and enrollment into a coordinated process. Without that infrastructure, faster approvals produce faster shelf-ready therapies, not faster treatment.

What modernizing patient access actually requires

If the US clinical trial system is going to regain competitiveness, regulatory modernization needs a counterpart on the patient-access side. Three structural changes would make a measurable difference.

Integrated patient-finding workflows. The current model of disconnected recruitment vendors, standalone screening tools, and separate genetic testing providers creates fragmentation at every step. What sponsors need is a coordinated system that connects referral, prescreening, genetic testing, and enrollment within a single infrastructure, so that each step feeds into the next without manual handoffs or data loss.

Scalable rare disease identification. For genetically stratified therapies, patient finding depends on screening at scale. This means building systems that can deploy at-home genetic testing, manage sample logistics across geographies, and integrate results directly into eligibility workflows. Treating genetic testing as a disconnected operational step, rather than an integrated part of the enrollment pathway, slows every program it touches.

Persistent patient engagement beyond single trials. The current trial model treats patient relationships as disposable. Once a trial ends, the connection to participants typically ends with it. For rare disease programs, where the eligible population is small and every qualified patient matters, this is a structural waste. Building systems that maintain compliant, ongoing relationships with participants across studies creates a recontactable asset that compounds in value over time, rather than resetting with each new program.

Impact and next steps

Operation Trailblazer represents the most significant federal investment in US clinical trial infrastructure in years. Its focus on regulatory modernization, data interoperability, and development pathway reform addresses real barriers. But the competitive gap the US faces is not only about how fast therapies are approved. It is about how effectively the system connects approved therapies with patients who need them.

For rare disease and precision medicine programs in particular, the bottleneck has shifted. The science is advancing faster than the patient-finding infrastructure can support. Faster regulatory timelines will create more approved therapies. Whether those therapies reach patients in time depends on whether the infrastructure for finding, screening, and enrolling them evolves at the same pace.

The question for sponsors, policymakers, and the clinical operations community is whether the next phase of modernization will address this gap directly, or continue to treat patient access as a downstream problem that solves itself.

Conclusion

Operation Trailblazer is a necessary step toward rebuilding US competitiveness in clinical trials. THRIVE, in particular, signals a commitment to accelerating development pathways for precision genetic medicines that could transform rare disease treatment. These are meaningful developments.

However, accelerating the regulatory pathway without equally modernizing the patient-finding infrastructure means faster approvals will continue to outpace patient access. For rare disease sponsors, clinical operations leaders, and the patients who depend on these therapies, closing this gap is the next critical challenge.

Planning a rare disease or precision medicine trial? Let’s talk about how to make patient finding part of the infrastructure from day one.